Published in Biotech Business Week, August 9th, 2004
This oncology target was validated through collaboration between Cancer Research U.K. and CRT's Development Laboratory. Genentech plans to evaluate the potential of protein therapeutics directed to this target.
Harpal Kumar, CEO of CRT, commented, "CRT is delighted to have completed its first licensing partnership with Genentech for a therapeutic target. This partnership...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.